Biomea Fusion Inc.

09/12/2024 | Press release | Distributed by Public on 09/12/2024 21:01

Biomea Fusion Announces Preliminary Data from Ongoing COVALENT-103 Study of Investigational Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia

Read this content
Click here to read the original version at the source's official website. The text of this article is not available at the moment.